|
AU2016200596A1
|
|
Topical composition containing ibuprofen
|
|
WO2016112201A1
|
|
Techniques and systems for transdermal delivery involving treatment of psoriasis, skin cancer, and other indications
|
|
AU2015203547A1
|
|
Topical composition containing ibuprofen
|
|
AU2015202451A1
|
|
Transdermal delivery of beneficial substances effected by a hostile biophysical environment
|
|
CN105377233A
|
|
Transdermal formulations of fluticasone
|
|
EP2968130A1
|
|
Transdermal delivery of sildenafil and other phosphodiesterase type 5 inhibitors
|
|
US2013289059A1
|
|
Beneficial effects of increasing local blood flow
|
|
AU2012201048A1
|
|
Transdermal delivery of beneficial substances effected by a hostile biophysical environment
|
|
EP3721893A1
|
|
Treatment of erectile dysfunction
|
|
CN103442722A
|
|
COX-2 inhibitors and related compounds, and systems and methods for delivery thereof
|
|
WO2012092527A1
|
|
Delivery of treatments transdermally for fungal infections and other indications
|
|
WO2012092523A1
|
|
Systems and methods for treatment of allergies and other indications
|
|
WO2012092526A1
|
|
Methods and systems for treatment of migraines and other indications
|
|
US2011028548A1
|
|
Beneficial effects of increasing local blood flow
|
|
CN104069060A
|
|
Surface composition containing ibuprofen
|
|
WO2010151241A1
|
|
Topical composition containing naproxen
|
|
WO2010151240A1
|
|
Topical composition containing ibuprofen
|
|
EP2630960A1
|
|
Transdermal Delivery of Beneficial Substances Effected by a Hostile Biophysical Environment
|
|
EP1732577A2
|
|
Topical delivery of l-arginine to improve body and skin appearance
|
|
US7914814B2
|
|
Topical delivery of arginine of cause beneficial effects
|
